Compare Dry Eye

6 products »

close Created with Sketch.

Cequa

Sun Ophthalmics

Cequa (cyclosporine ophthalmic solution) 0.09% was the first and only dry eye treatment to combine cyclosporine A with nanomicellar technology. It is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye) and comes as a preservative-free, aqueous solution in a single-use vial. According to the compant, the nanomicellar formulation allows the CsA molecule to overcome solubility challenges, penetrate the eye’s aqueous layer and prevents the release of the active lipophilic molecule prior to penetration.

At-a-Glance
  • Mechanism of Action: Cyclosporine is a calcineurin inhibitor immunosuppressant agent when administered systemically. In patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, topical administration of cyclosporine is thought to act as a partial immunomodulator. The exact mechanism of action is not known.
  • Dosage: One drop twice daily (approximately 12 hours apart) into each eye.

Details

FDA

Yes

CE Mark

Not specified

Active Ingredients

Nanomicellar cyclosporine

Application

Topical

Status

Prescription

Strength

0.09%

Company Information

Contact the company for additional information, availability, or pricing:

Sun Ophthalmics

sunophthalmics.com

2 Independence Way

Princeton, NJ 08540